---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-146350"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:24:59.460944+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inovio Q1 net loss $79.1M ($0.36/share); CEO Kim resigns, Shea appointed; discontinues INNOVATE trial

## Summary
- Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.
- CEO J. Joseph Kim resigns; Jacqueline Shea (former COO) appointed President and CEO; Shea base salary $700K.
- Phase 3 INNOVATE trial for COVID-19 vaccine discontinues; prioritize heterologous booster strategy.
- VGX-3100 BLA for cervical HSIL not expected in 2023; REVEAL2 amended to biomarker-selected population.
- Cash and investments $360.4M at Mar 31, 2022, down from $401.3M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001193125-22-146350
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/d259881d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-146350
- JSON: https://secwatch.observer/filing/0001193125-22-146350.json
- Plain text: https://secwatch.observer/filing/0001193125-22-146350.txt

## Key facts
- Executive change
  Jacqueline E. Shea was appointed as President and Chief Executive Officer at INOVIO PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm
- Executive change
  J. Joseph Kim resigned as President, Chief Executive Officer and Director at INOVIO PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: President, Chief Executive Officer and Director
  source text: J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.